Last updated: March 2, 2026
What is NDC 00143-9291?
NDC 00143-9291 refers to Vyvgart (efgartigimod alfa-fcab), marketed by argenx, approved by the FDA for the treatment of generalized myasthenia gravis (gMG) in adults with anti-AChR antibodies. It is a monoclonal antibody targeting the neonatal Fc receptor (FcRn), designed to reduce pathogenic IgG levels.
Current Market Landscape
Competitive Position
Vyvgart competes within the autoimmune neuromuscular disease segment, alongside therapies such as:
- Mestinon (pyridostigmine) – symptomatic management
- Tensilon (edrophonium) – diagnostic agent
- Eculizumab (Soliris) – for refractory cases of gMG
- Zinbryta (daclizumab) – withdrawn due to safety concerns
- Sutimlimab (Ultomiris) – investigational for autoimmune conditions
Regulatory and Clinical Context
- FDA Approval Date: December 2022
- Indications: Generalized myasthenia gravis in adults with anti-AChR antibodies
- Dosing: IV administration, often monthly
- Pricing: List price approximately $16,500 per dose (as of Q1 2023)[1]
Market Size
- Estimated prevalence of gMG in the U.S.: 20,000–30,000 patients, with about 60–80% harboring anti-AChR antibodies
- Target population: Patients with confirmed anti-AChR status, mostly refractory or intolerant to existing therapies
Reimbursement Environment
- Payers view Vyvgart as an advanced therapy for refractory gMG
- Coverage depends on prior authorization and specialty pharmacy distribution
- Reimbursement rates generally align with high-cost biologics for rare diseases
Price Projections
Base Price Analysis
- Current list price: approximately $16,500 per dose
- Dosing schedule: Typically monthly (about 12 doses/year)
- Estimated annual drug cost per patient: roughly $198,000
Price Trends and Potential Adjustments
- Launch pricing: Common for biologics, initial list prices tend to stay stable for 12–24 months
- Market expansion: Possible price decreases with increased competition or biosimilar entries
- Rebate and discount influence: Likely to reduce net prices by 20–30%
Projected Price Range for the Next 3 Years
| Year |
Estimated List Price per Dose |
Approximate Annual Cost |
Key Drivers |
| 2023 |
$16,500 |
$198,000 |
Initial launch price, no significant discounts |
| 2024 |
$15,000–$16,000 |
$180,000–$192,000 |
Competitive pressure, reimbursement adjustments |
| 2025 |
$14,500–$15,500 |
$174,000–$186,000 |
Biosimilar development, market penetration |
Potential Market Entry of Biosimilars
- Biosimilars for monoclonal antibodies targeting FcRn could launch as early as 2027–2029.
- Biosimilar prices often discount originator by 20–40%, reducing costs for payers and patients.
Market Dynamics Impacting Pricing
- Reimbursement policies may tighten based on new formulary guidelines.
- Patient access programs may lower out-of-pocket expenses but could influence list prices.
- Manufacturing and distribution costs influence future pricing stability.
Summary of Risks and Opportunities
| Risk |
Impact |
Opportunity |
| Entry of biosimilars |
Downward pressure on list prices |
Cost reductions for payers and patients |
| Regulatory delays or restrictions |
Limited market penetration |
Pricing stability for longer periods |
| Market expansion beyond gMG segment |
Increased volume, potential price concessions |
Greater revenue potential |
Key Takeaways
- Vyvgart’s initial list price is approximately $16,500 per dose, with annual treatment costs near $200,000.
- Market dynamics suggest potential price reductions of 10–15% within 2 years and more significant discounts with biosimilar competition.
- Reimbursement and payer policies will heavily influence actual net prices.
- Market expansion into broader autoimmune indications could alter demand and pricing power.
FAQs
Q1: Will Vyvgart’s price decline significantly in the next two years?
A1: A 10–15% reduction is probable due to market competition and payer negotiations.
Q2: When are biosimilars for FcRn inhibitors expected?
A2: Early biosimilar development in this space suggests launches around 2027–2029.
Q3: How does Vyvgart compare to eculizumab in market positioning?
A3: Vyvgart targets a broader patient base with a convenient IV schedule, while eculizumab targets more refractory cases with higher costs.
Q4: What factors could mitigate pricing declines?
A4: Limited biosimilar development, high clinical efficacy, and favorable reimbursement may stabilize prices.
Q5: Are there opportunities for strategic partnerships?
A5: Yes—especially with specialty pharmacies, distribution channels, and payers seeking to optimize costs and patient access.
References
[1] Company Filings, March 2023.
